UTRECHT, The Netherlands & CAMBRIDGE, England & ROME, Italy--(BUSINESS WIRE)--PanGenetics B.V. and Lay Line Genomics S.p.A. (LLG) jointly announced today that the companies have entered into a collaboration in the field of therapeutic antibodies for the treatment of pain. Under the terms of the collaboration agreement, LLG has granted to PanGenetics exclusive rights to Hu-alphaD11, a humanized antibody against nerve growth factor (NGF) that has shown very promising effects in preclinical animal models of inflammatory and chronic pain. The companies will work together on the preclinical program and PanGenetics will assume full responsibility for the clinical development and commercialization of Hu-alpha-D11. In addition to research funding and an upfront payment, LLG will receive undisclosed milestone payments and royalties on commercial sales.
